<p>Humacyte, Inc.（納斯達克股票代碼：HUMA - 獲取免費報告）的股價在週二交易中下跌了 8.9%。股價最低達到 5.48 美元，最後交易價為 5.51 美元。在交易過程中，共有 1,366,508 股股票交易，較平均交易量 2,181,580 股下降了 37%。該股票此前收盤價為 6.05 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>近期有幾位研究分析師發佈了關於該公司的報告。BTIG 研究將 Humacyte 的目標股價從 8.00 美元上調至 11.00 美元，並在 7 月 15 日星期一的一份研究報告中給予該股票 “買入” 評級。康泰菲茲傑拉德重申了對 Humacyte 的 “超重” 評級，並在 7 月 2 日星期二的一份報告中設定了 7.00 美元的價格目標。最後，Benchmark 重申了對 Humacyte 的 “買入” 評級，並在 8 月 12 日星期一的一份研究報告中設定了 15.00 美元的價格目標。一位研究分析師對該股票進行了持有評級，而另外四位則給予了該股票買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “中等買入”，目標股價為 8.60 美元。</p>
<p><strong>查看我們關於 HUMA 的最新報告</strong></p>
<h2>Humacyte 股價下跌 8.8%</h2>
<p>該公司的市值為 6.5734 億美元，市盈率為-5.57，β係數為 1.52。該股票的 50 天移動平均價格為 6.86 美元，200 天移動平均價格為 5.47 美元。該公司的流動比率為 5.41，速動比率為 5.41，負債權益比為 0.61。</p>
<h2>內部人員活動</h2>
<p>另外，首席執行官 Laura E. Niklason 於 6 月 11 日星期二以每股 7.08 美元的平均價格出售了 358,630 股股票。此次交易總價值為 2,539,100.40 美元。交易完成後，首席執行官直接持有公司股票 4,830,658 股，價值 34,201,058.64 美元。該交易已在提交給美國證券交易委員會（SEC）的文件中披露，可通過 SEC 網站查看。此外，董事 Brady W. Dougan 於 6 月 12 日星期三以每股 7.30 美元的平均價格出售了 271,518 股公司股票。此次交易總價值為 1,982,081.40 美元。交易完成後，該董事直接持有公司股票 4,559,140 股，價值 33,281,722 美元。該交易已在提交給 SEC 的文件中披露，可通過此超鏈接查看。此外，首席執行官 Laura E. Niklason 於 6 月 11 日星期二以每股 7.08 美元的平均價格出售了 358,630 股 Humacyte 股票。此次交易總價值為 2,539,100.40 美元。交易完成後，首席執行官在公司中持有 4,830,658 股股票，價值 34,201,058.64 美元。上一季度內部人員共出售了價值 10,508,440 美元的 1,551,415 股公司股票。目前公司股份的 23.10% 由內部人員持有。</p>
<h2>對 Humacyte 的對沖基金看法</h2>
<p>對沖基金和其他機構投資者最近對其股票持倉進行了調整。nVerses Capital LLC 在第二季度購入了 Humacyte 股票，價值 28,000 美元。Victory Capital Management Inc.在第四季度購入了 Humacyte 股票，價值約 29,000 美元。Kovitz Investment Group Partners LLC 在第四季度購入了 Humacyte 股票，價值約 35,000 美元。中國通用資產管理有限公司在第一季度將其對 Humacyte 的持股比例提高了 65.9%。中國通用資產管理有限公司現在擁有公司股票 19,883 股，價值 62,000 美元，比上一季度增加了 7,897 股。最後，Hartline Investment Corp 在第一季度購入了 Humacyte 股票，價值約 70,000 美元。目前，44.71% 的股份由對沖基金和其他機構投資者持有。</p>
<h2>Humacyte 公司簡介（獲取免費報告）</h2>
<p>Humacyte, Inc 致力於開發和製造用於治療多種解剖部位疾病和症狀的離體、可植入和生物工程人類組織。該公司利用其專有的科學技術平台工程和製造人類無細胞血管（HAVs），可植入患者體內而不引起異物反應或導致免疫排斥。</p>
<h2>推薦故事</h2>
<ul>
<li>我們喜歡的五隻股票</li>
<li>股市板塊：它們是什麼以及有多少個</li>
<li>內部人員正在購買的 3 只小市值股票</li>
<li>什麼是債券市場假日？如何投資和交易</li>
<li>分析師預測西部數據的巨大增長——不要錯過</li>
<li>現在購買寶潔股票，趁它創下新的歷史高點之前</li>
<li>今天市場上看漲投資者必須擁有的 3 只股票</li>
</ul>
<p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 唯一值得購買的 AI 公司（由波特公司提供）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ2"/></p>
<h2>您現在是否應該投資 1,000 美元購買 Humacyte 股票？</h2>
<p>在考慮購買 Humacyte 股票之前，您可能想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的五隻股票...而 Humacyte 不在名單上。</p>
<p>儘管 Humacyte 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

HUMA

<p>Humacyte (NASDAQ:HUMA) 週二股價下跌了 8.9%，最低交易價為$0.48，收盤價為$0.51。此次下跌的交易量為 1,366,508 股，遠低於平均交易量 2,181,580 股。儘管最近出現下跌，但幾位分析師仍然維持對該股票的 “買入” 評級，一致目標價為$0.60。該公司繼續開發用於醫療用途的生物工程人體組織</p>

<p>Humacyte, Inc. (NASDAQ:HUMA - Get Free Report)'s stock price fell 8.9% during trading on Tuesday . The stock traded as low as $5.48 and last traded at $5.51. 1,366,508 shares changed hands during trading, a decline of 37% from the average session volume of 2,181,580 shares. The stock had previously closed at $6.05.</p>
<div class="lb-trans"><p>Humacyte, Inc.（納斯達克股票代碼：HUMA - 獲取免費報告）的股價在週二交易中下跌了 8.9%。股價最低達到 5.48 美元，最後交易價為 5.51 美元。在交易過程中，共有 1,366,508 股股票交易，較平均交易量 2,181,580 股下降了 37%。該股票此前收盤價為 6.05 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research analysts recently issued reports on the company. BTIG Research raised their target price on Humacyte from $8.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, July 15th. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $7.00 price target on shares of Humacyte in a report on Tuesday, July 2nd. Finally, Benchmark reiterated a &#34;buy&#34; rating and set a $15.00 price objective on shares of Humacyte in a research report on Monday, August 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $8.60.</p>
<div class="lb-trans"><p>近期有幾位研究分析師發佈了關於該公司的報告。BTIG 研究將 Humacyte 的目標股價從 8.00 美元上調至 11.00 美元，並在 7 月 15 日星期一的一份研究報告中給予該股票 “買入” 評級。康泰菲茲傑拉德重申了對 Humacyte 的 “超重” 評級，並在 7 月 2 日星期二的一份報告中設定了 7.00 美元的價格目標。最後，Benchmark 重申了對 Humacyte 的 “買入” 評級，並在 8 月 12 日星期一的一份研究報告中設定了 15.00 美元的價格目標。一位研究分析師對該股票進行了持有評級，而另外四位則給予了該股票買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “中等買入”，目標股價為 8.60 美元。</p>
</div><p><strong>Check Out Our Latest Report on HUMA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 HUMA 的最新報告</strong></p>
</div><h2>Humacyte Stock Down 8.8 %</h2>
<div class="lb-trans"><h2>Humacyte 股價下跌 8.8%</h2>
</div><p>The company has a market cap of $657.34 million, a P/E ratio of -5.57 and a beta of 1.52. The stock's 50-day moving average price is $6.86 and its 200-day moving average price is $5.47. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61.</p>
<div class="lb-trans"><p>該公司的市值為 6.5734 億美元，市盈率為-5.57，β係數為 1.52。該股票的 50 天移動平均價格為 6.86 美元，200 天移動平均價格為 5.47 美元。該公司的流動比率為 5.41，速動比率為 5.41，負債權益比為 0.61。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部人員活動</h2>
</div><p>In other news, CEO Laura E. Niklason sold 358,630 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $7.08, for a total value of $2,539,100.40. Following the completion of the sale, the chief executive officer now directly owns 4,830,658 shares of the company's stock, valued at $34,201,058.64. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Brady W. Dougan sold 271,518 shares of the company's stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total value of $1,982,081.40. Following the completion of the transaction, the director now directly owns 4,559,140 shares of the company's stock, valued at $33,281,722. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 358,630 shares of Humacyte stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $7.08, for a total value of $2,539,100.40. Following the sale, the chief executive officer now owns 4,830,658 shares in the company, valued at $34,201,058.64. The disclosure for this sale can be found here. Insiders sold a total of 1,551,415 shares of company stock worth $10,508,440 over the last quarter. 23.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>另外，首席執行官 Laura E. Niklason 於 6 月 11 日星期二以每股 7.08 美元的平均價格出售了 358,630 股股票。此次交易總價值為 2,539,100.40 美元。交易完成後，首席執行官直接持有公司股票 4,830,658 股，價值 34,201,058.64 美元。該交易已在提交給美國證券交易委員會（SEC）的文件中披露，可通過 SEC 網站查看。此外，董事 Brady W. Dougan 於 6 月 12 日星期三以每股 7.30 美元的平均價格出售了 271,518 股公司股票。此次交易總價值為 1,982,081.40 美元。交易完成後，該董事直接持有公司股票 4,559,140 股，價值 33,281,722 美元。該交易已在提交給 SEC 的文件中披露，可通過此超鏈接查看。此外，首席執行官 Laura E. Niklason 於 6 月 11 日星期二以每股 7.08 美元的平均價格出售了 358,630 股 Humacyte 股票。此次交易總價值為 2,539,100.40 美元。交易完成後，首席執行官在公司中持有 4,830,658 股股票，價值 34,201,058.64 美元。上一季度內部人員共出售了價值 10,508,440 美元的 1,551,415 股公司股票。目前公司股份的 23.10% 由內部人員持有。</p>
</div><h2>Hedge Funds Weigh In On Humacyte</h2>
<div class="lb-trans"><h2>對 Humacyte 的對沖基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC bought a new stake in shares of Humacyte in the second quarter valued at $28,000. Victory Capital Management Inc. bought a new stake in shares of Humacyte in the fourth quarter valued at approximately $29,000. Kovitz Investment Group Partners LLC bought a new stake in shares of Humacyte in the fourth quarter valued at approximately $35,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Humacyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company's stock valued at $62,000 after buying an additional 7,897 shares in the last quarter. Finally, Hartline Investment Corp bought a new position in Humacyte in the 1st quarter worth approximately $70,000. 44.71% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近對其股票持倉進行了調整。nVerses Capital LLC 在第二季度購入了 Humacyte 股票，價值 28,000 美元。Victory Capital Management Inc.在第四季度購入了 Humacyte 股票，價值約 29,000 美元。Kovitz Investment Group Partners LLC 在第四季度購入了 Humacyte 股票，價值約 35,000 美元。中國通用資產管理有限公司在第一季度將其對 Humacyte 的持股比例提高了 65.9%。中國通用資產管理有限公司現在擁有公司股票 19,883 股，價值 62,000 美元，比上一季度增加了 7,897 股。最後，Hartline Investment Corp 在第一季度購入了 Humacyte 股票，價值約 70,000 美元。目前，44.71% 的股份由對沖基金和其他機構投資者持有。</p>
</div><h2>Humacyte Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Humacyte 公司簡介（獲取免費報告）</h2>
</div><p>Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.</p>
<div class="lb-trans"><p>Humacyte, Inc 致力於開發和製造用於治療多種解剖部位疾病和症狀的離體、可植入和生物工程人類組織。該公司利用其專有的科學技術平台工程和製造人類無細胞血管（HAVs），可植入患者體內而不引起異物反應或導致免疫排斥。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Humacyte</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>3 Small Cap Stocks That Insiders Are Buying</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Analysts Forecast Big Upside for Western Digital—Don’t Miss Out</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>3 Must-Own Stocks for Bullish Investors in Today's Market</li>
</ul>
<div class="lb-trans"><h2>推薦故事</h2>
<ul>
<li>我們喜歡的五隻股票</li>
<li>股市板塊：它們是什麼以及有多少個</li>
<li>內部人員正在購買的 3 只小市值股票</li>
<li>什麼是債券市場假日？如何投資和交易</li>
<li>分析師預測西部數據的巨大增長——不要錯過</li>
<li>現在購買寶潔股票，趁它創下新的歷史高點之前</li>
<li>今天市場上看漲投資者必須擁有的 3 只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科技和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ The only AI company to buy (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 唯一值得購買的 AI 公司（由波特公司提供）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9246&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Humacyte right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購買 Humacyte 股票？</h2>
</div><p>Before you consider Humacyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Humacyte 股票之前，您可能想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的五隻股票...而 Humacyte 不在名單上。</p>
</div><p>While Humacyte currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Humacyte 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Humacyte（納斯達克代碼：HUMA）股價下跌 8.9%